



Passive protection against anthrax in mice with plasma derived from horses hyper-immunized against *Bacillus anthracis* Sterne strain

Marc Caldwell¹, Terri Hathcock¹ and Kenny V. Brock²

¹Department of Pathobiology, Auburn University, Auburn, AL, United States of America

²Edward Via College of Osteopathic Medicine, Auburn University, Auburn, AL, United States of America

ABSTRACT

In this study, equine source polyclonal anti-*Bacillus anthracis* immunoglobulins were generated and utilized to demonstrate passive protection of mice in a lethal challenge assay. Four horses were hyper-immunized with *B. anthracis* Sterne strain for approximately one year. The geometric mean anti-PA titer in the horses at maximal response following immunization was 1:77,936 (Log₂ mean titer 16.25, SEM ± 0.25 95% CI [15.5 –17.0]). The geometric mean neutralizing titer at maximal response was 1:128 (Log₂ mean titer 7, SEM ± 0.0, 95% CI 7). Treatment with hyper-immune plasma or purified immunoglobulins was successful in passively protecting A/J mice from a lethal *B. anthracis* Sterne strain challenge. The treatment of mice with hyper-immune plasma at time 0 h and 24 h post-infection had no effect on survival, but did significantly increase mean time to death ($p < 0.0001$). Mice treated with purified immunoglobulins at time 0 h and 24 h post-infection in showed significant increase in survival rate ($p < 0.001$). Bacterial loads in lung, liver and spleen tissue were also assessed and were not significantly different in mice treated with hyper-immune plasma from placebo treated control mice. Mice treated with purified antibodies demonstrated mean colony forming units/gram tissue fourfold less than mice receiving placebo treatment ($p < 0.0001$). Immunotherapeutics harvested from horses immunized against *B. anthracis* Sterne strain represent a rapidly induced, inexpensive and effective expansion to the arsenal of treatments against anthrax.

Submitted 23 March 2016
Accepted 19 September 2017
Published 15 December 2017

Corresponding author
Marc Caldwell, mcaldwell@utk.edu

Academic editor
Pankaj Goyal

Additional Information and
Declarations can be found on
page 14

DOI 10.7717/peerj.3907

© Copyright
2017 Caldwell et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Immunology, Infectious Diseases

Keywords Anthrax, Equine, Mouse lethal challenge, Passive immunotherapy, *B. anthracis* Sterne strain

INTRODUCTION

Antibiotic therapy is the foundation for post-exposure prophylaxis and treatment of anthrax infection (*Hendricks et al., 2014; Pillai et al., 2015*). Removal of vegetative bacteria from circulation is necessary to curtail systemic spread and decrease morbidity and mortality (*Bryskier, 2002; Weiss et al., 2011*). In its vegetative state, *Bacillus anthracis* constitutively produces the anthrax exotoxins, lethal toxin and edema toxin, and these toxins continue to contribute to pathogenesis and ongoing illness beyond clearance of the live organisms (*Moayeri et al., 2015*). Neutralization of the three toxin protein subunits

(lethal factor, LF, edema factor, EF, and protective antigen, PA) via immunization and administration of passive monoclonal and polyclonal immunotherapeutics improves the clinical outcomes of systemic forms of the disease ([Hendricks et al., 2014](#); [Huang et al., 2015](#)). Efficacy studies of passive and active immunity indicate that PA is the most important target for neutralizing both lethal and edema toxins ([Ivins et al., 1992](#); [Turnbull et al., 1986](#); [Turnbull et al., 1988](#)). Protective antigen is the common subunit for each toxin and mediates cellular translocation of the effector molecules through the formation of intra-phagocytic pores ([Pezard, Berche & Mock, 1991](#)). Effective antibody interference with PA prevents the manifestation of the *B. anthracis* toxin pathogenesis ([Albrecht et al., 2007](#); [Karginov et al., 2004](#)). In addition, neutralization of LF and EF have each been independently shown to improve survivability and reduce morbidity ([Albrecht et al., 2007](#); [Leysath et al., 2011](#); [Pohl et al., 2013](#)). A combination of these targets may provide the most robust protection, but to date targeting PA has been the focus of most therapeutic advances ([Pohl et al., 2013](#); [Staats et al., 2007](#)).

There are currently two US Food and Drug Administration approved immunotherapeutics indicated for treatment of and prophylaxis against inhalational anthrax in adults and children in combination with appropriate antibiotics. Raxibacumab (GlaxoSmithKline, London, UK) is a human IgG1 λ monoclonal antibody produced in a murine hybridoma expression system that specifically binds PA ([US-FDA, 2013](#)). The efficacy of raxibacumab has been evaluated in challenge studies utilizing toxin administration or fully virulent *B. anthracis* inoculation in rats, rabbits, dogs and non-human primates ([Corey et al., 2013](#); [Cui et al., 2005](#); [Kummerfeldt, 2014](#); [Mazumdar, 2009](#); [Migone et al., 2015](#); [Migone et al., 2009](#); [Remy et al., 2015](#)). Anthrax Immune Globulin Intravenous (AVIG, Anthrasil, Cangene Corporation, Winnipeg, Manitoba, Canada) is a human polyclonal antiserum derived from the plasma of persons immunized with anthrax vaccine adsorbed (AVA, BioThrax, Emergent BioSolutions Inc., Rockville, MD, USA; [US-FDA, 2015](#)). Its efficacy has been evaluated in rabbits and non-human primates in the treatment and prophylaxis of fully virulent *B. anthracis* challenges ([Kammanadiminti et al., 2014](#); [Mytle et al., 2013](#)). Because AVA is an inactivated whole cell lysate of a fully toxigenic and encapsulated strain of *B. anthracis*, plasma derived from individuals immunized with this product contains multiple epitopic targets including all three toxins subunits as well as other capsular and non-capsular antigens ([Wright et al., 2010](#)).

The use of equine antisera for the treatment and prevention of human infectious disease pre-dates the antibiotic era ([Von Stabsarzt, 1991](#)). In 1901, Emil von Behring received the first Nobel Prize in Physiology and Medicine for developing polyclonal antibodies (pAbs) and using them as a treatment against diphtheria and tetanus ([Von Behring, 2008](#)). Shortly after an Italian protégé of von Behring, Achille Sclavo, began work on developing a donkey based antiserum against anthrax to stem the effect the disease was creating in Italy at the time ([Ragazzi, 1954](#)). The first report of successful treatment using Sclavo's anti-serum appeared in the *British Medical Journal* in 1905 describing the treatment and recovery of a man with cutaneous anthrax ([Mitchell, 1905](#)). Reports of the observational success of anti-serum in the treatment of cutaneous and systemic anthrax continued up until 1954 ([Hodgson, 1941](#); [Canright, 1928](#); [Santee, 1923](#); [Sclavo, 1954](#)). Equine-based hyperimmune

products continue to be important therapeutic modalities for toxin based diseases such as tetanus, botulism, and snake envenomation, as well as some viral disease such as rabies (Arnon, 2007; CDC, 2010; CDC, 2011). Due to low manufacturing cost, simplified logistics, high antibody yield and low risk of transfusion infections, the hyperimmunization of horses against anthrax represents a compelling alternative compared to the costly manufacture of monoclonal antibodies and the limited supply of AVA vaccinated plasma donors. Developing nations with limited resources and biomedical infrastructure could utilize an equine-derived manufacturing process to gain access to these types of therapies. This study describes a proof-of-concept analysis whereby horses were immunized with the veterinary *B. anthracis* Sterne 34F2 strain spore vaccine to develop a polyclonal hyperimmune plasma. This plasma was assessed for its anti-PA IgG titer as well as lethal toxin neutralizing titer. Then the hyperimmune plasma and plasma-derived purified IgG immunoglobulins were assessed for efficacy in passively protecting A/J mice from a lethal intranasal (IN) and subcutaneous (SC) *B. anthracis* Sterne strain spore challenge.

MATERIALS AND METHODS

Equine immunization

All procedures described within this study involving the use of animals were approved by Auburn University Institutional Animal Care and Use Committee (protocol #2012–2105). Four Percheron draft mares were immunized with 1.0 ml of *B. anthracis* Sterne strain spore vaccine (Anthrax Spore Vaccine, Colorado Serum Company, Denver, CO, USA) once monthly for a total of 12 immunizations over the course of approximately 302 days. Whole blood samples were collected at monthly intervals (12 total blood collections) for titer analysis. Samples were centrifuged at $5,000 \times g$ for 20 min, plasma separated, and stored at -80°C until ready for analysis. Plasma used for negative controls were obtained from two un-immunized horses (control plasma, CON) as described for principal samples.

Quantification of anti-PA IgG antibodies

A 96-well plate (Immulon 2 HB Southern Biological, Birmingham, AL, USA) was coated with 100 μl of rPA coating solution (1 $\mu\text{g}/\text{ml}$ in PBS, List Biological Laboratories, Inc. Campbell, CA, USA). Plates were incubated overnight at 4°C . Principal samples (1:500) were added in triplicate. Naïve control plasma samples (1:50) were also added in triplicate. Twofold dilutions were made across the plate, with 100 μl discarded from the last well. The plate was then incubated at 37°C for 1 h. Goat anti-equine IgG antibody conjugated to HRP (Jackson ImmunoResearch Lab, INC, West Grove, PA, USA) was added to each well and the plate was incubated again at 37°C for 1 h. Finally, ABTS (Thermo Scientific, Rockford, IL, USA) was added, followed by a brief incubation and determination of optic density performed (405 and 550 nm, Bio-Tek Elx800 plate reader, Winooski, VT, USA). A reference plasma or positive standard was developed from a pool of vaccinated horses and was subjected to a series of assays in order to establish a titration curve. Briefly, eight rPA-coated microtiter plates were prepared. Following overnight incubation, approximately 200 μl of the reference plasma that had been diluted to 1:500 was added to the first well of three rows on each plate then two-fold serial dilutions carried out. In this way, each

Table 1 Reciprocal end point anti-protective antigen titers for horses immunized monthly with 1.0 ml Sterne strain *Bacillus anthracis* spore vaccine. Plasma from each horse was subjected to the anti-PA IgG indirect ELISA for each time point. Reciprocal titers were achieved from the geometric mean of three replicates of each sample.

Days of Immunization	Mean Reciprocal Titers					
	AX1	AX2	AX3	AX4	Naive 1	Naive 2
0	0	0	0	0	0	0
21	2,000	0	500	500	0	0
50	16,000	32,000	32,000	32,000	0	0
78	32,000	16,000	32,000	32,000	0	0
106	64,000	64,000	32,000	64,000	0	0
134	32,000	64,000	16,000	16,000	0	0
162	64,000	64,000	32,000	64,000	0	0
190	32,000	64,000	64,000	128,000	0	0
218	64,000	64,000	128,000	64,000	0	0
246	32,000	64,000	32,000	32,000	0	0
274	32,000	64,000	128,000	32,000	0	0
302	64,000	32,000	128,000	16,000	0	0

plate contained reference plasma samples in triplicate. A titration curve was drawn using individual absorbance values at each dilution point from the 24 assays relating the log₁₀ experimental units/mL vs. log₁₀ OD. Once the titration curve was established a series of experiments were conducted to establish the limit of detection. Two samples of naïve horse plasma were diluted 1:50 and subjected to the anti-PA IgG ELISA in triplicate in two microtiter plates, on each of the five days within two weeks. Fresh dilutions and rPA-coated plates were individually prepared and used daily. The limit of detection was estimated by interpolating the mean of 60 absorbance values, plus three standard deviations, in a titration curve of reference plasma relating log₁₀ -assigned units/ml per well vs. log₁₀ absorbance. The antilog of the interpolated value was subsequently corrected by the dilution of the sample (1:50). End point titers were calculated as the highest dilutions at which the OD values were two fold higher the interpolated limit of detection. The geometric mean for each sample was calculated from the estimated end-point titer from triplicate samples. Once established, the reference plasma was used as a positive standard along with each of the naïve horse plasma samples as negative reference standards in every assay thereafter. [Table 1](#) lists the estimated geometric mean anti-PA IgG log titers.

Antibody mediated neutralization of lethal toxin

Lethal toxin neutralizing titers were determined by modifying a previously described assay for human and rabbit antisera ([Hering et al., 2004](#)). Mouse macrophage J774A.1 cells (ATCC TIB-67) were obtained and grown in high-glucose Dulbecco's modified Eagle medium containing l-glutamine and supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (10,000 U/ml penicillin G sodium and 10,000 µg/ml streptomycin sulfate).

Table 2 Reciprocal endpoint neutralizing titers for horses immunized with 1.0 ml Sterne strain *Bacillus anthracis* spore vaccine. J774A.1 cells were exposed to *B. anthracis* lethal toxin (1.0 µg/ml PA and 1.0 µg/ml LF) that had been pre-incubated with individual hyper-immune plasma samples. alamarBlue was added overnight and the amount of reduced alamarBlue was measured as an indicator of metabolic activity. The neutralization titer, defined as the highest dilution conveying 50% protection from the LF-mediated lysis, is plotted for each plasma sample at each time point. Each titer represents the geometric mean for three replicates.

Days of immunization	Mean reciprocal titers					
	AX1	AX2	AX3	AX4	Naïve 1	Naïve 2
0	0	0	0	0	0	0
21	32	32	32	32	0	0
50	128	128	128	128	0	0
78	128	128	128	128	0	0
106	128	128	128	128	0	0
134	128	128	128	128	0	0
162	128	128	128	128	0	0
190	128	128	128	128	0	0
218	128	128	128	128	0	0
246	128	128	128	128	0	0
274	128	128	128	128	0	0
302	128	128	256	128	0	0

Two-fold dilutions of plasma (1:32) were prepared in supplemented DMEM. Recombinant protein solutions of rPA (1.0 µg/ml) and rLF (1.0 µg/ml) were added to the serum dilutions, and the mixtures were incubated for 10 min at 37 °C with shaking. Cells were diluted to 2×10^6 cells/ml, then added to a sterile 96-well tissue culture plate and incubated for 2 h. The media was removed and replaced with 100 µl media containing prepared toxin-plasma mixtures and incubated for 4 h at 37 °C in 5% CO₂. alamarBlue (80% solution in Hanks balanced salt solution; Trek Diagnostic Systems Inc., Westlake, OH, USA) was added at 10% of the well volume, and the cells were incubated for 20 h at 37 °C in 5% CO₂. Absorbance at 570 nm (to detect oxidized alamarBlue) and 595 nm (to detect reduced alamarBlue) was measured using a Bio-Tek Elx800 plate reader. Cells lysed by the addition of 10 µl of Triton X-100 were used as negative controls. As stated above, end point titers were determined as the highest dilutions at which the OD values were two fold higher the interpolated limit of detection for the assay. Assays were performed in triplicate. The geometric mean for each sample was calculated from the estimated end-point titer from triplicate samples. Table 2 lists the estimated geometric mean lethal toxin neutralizing log titers.

Passive protection assay

Purification and preparation of plasma and immunoglobulin treatments

Plasma treatments were prepared from four aliquots demonstrating the highest anti-PA IgG and neutralizing titer (1:128,000 and 1:128–1:256, respectively) and pooled immediately prior to administration. The placebo treatments were prepared from CON plasma and was

handled in the same manner. Administration of 0.8 ml of each was chosen as a maximum safely administered volume.

To produce the purified immunoglobulin samples, aliquots corresponding to those plasma samples used as treatments above were subjected to polyclonal protein A columns for affinity purification (Pierce Protein A Columns, Pierce-Thermo Scientific, Rockford, IL, USA). Fractions with the highest protein content were pooled and stored at -80°C until ready to use. Placebo treatments consisted of immunoglobulin fractions obtained from CON plasma that had been subjected to the same purification and preparation procedures.

Inoculum preparation

The challenge bacterium used was obtained from the veterinary vaccine *B. anthracis* Sterne strain 34F2 (Anthrax Spore Vaccine, Colorado Serum Company Denver, CO, USA). The procedure to determine the lethal dose 50 (LD₅₀) of the *B. anthracis* Sterne strain spores in A/J mice was slightly modified from that described by [Hewetson et al. \(2008\)](#) Briefly, mice received a range of spores suspended in PBS from 10 to 1×10^6 either intra-nasally (IN) or subcutaneously (SC). The estimated log₁₀ of the IN LD₅₀ from three independent studies was 3.5718 (upper and lower 95% CI: 4.1163 and 3.0351). For subsequent IN challenges an infectious dose of 4 LD₅₀, or approximately 1.5×10^4 spores was used. Additionally, the estimated log₁₀ of the SC LD₅₀ was 2.7383 (upper and lower 95% CI: 3.2232 and 2.1798). For subsequent SC challenges an infectious dose of approximately 2×10^3 spores was used. Stock preparations of both challenge inoculums were verified for spore concentration immediately before and after challenge procedures were performed.

B. anthracis challenge

Female A/J strain mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and were from 6–12 weeks age during these experiments. Mice were housed in ventilation controlled hepa-filtered biosafety cages with up to five animals per cage. The mice were divided into seven treatment groups for each route of challenge as described in [Tables S.1](#) and [S.2](#). Mice were randomly allocated to the following treatment groups: **Control (CON)** mice treated with plasma collected from horses naïve against *B. anthracis* ($n = 20$ in the plasma experiment, $n = 15$ in the purified IgG experiment); **Non-infected Treatment Control (Non-Infected)** mice received immune plasma ($n = 20$) or concentrated IgG ($n = 15$) and sterile PBS as a sham IN and SC inoculation; **Immune plasma**, mice receiving immune plasma were treated at 0 h (**Tx 0 h**) and 24 h (**Tx 24 h**) following IN or SC challenge ($n = 20$ for each challenge group); and **Purified Immunoglobulins**, mice receiving immunoglobulins were treated at 0 h (**IgG 0 h**) and 24 h (**IgG 24 h**) following IN or SC challenge ($n = 15$ for each group). All treatments were administered once at 0.8 ml volume in the right rear quadrant of the peritoneal cavity while mice were restrained. Treatments administered at 0 h were treated once concurrently at the time of challenge, while the 24 h treated groups received a single treatment at 24 h post-challenge.

Intranasal challenges were carried out by first anesthetizing each mouse (xylazine/ke-tamine combination, 10 mg/kg and 100 mg/kg respectively, IP) and depositing 30 μl PBS containing approximately 1.5×10^4 spores on the external nares. Mice were restrained until all the liquid was aspirated. Sham IN challenged mice were anesthetized and handled in an

identical manner, however 30 μ l of sterile PBS was deposited on the external nares. For SC infection, un-anaesthetized mice were injected with 100 μ l PBS containing approximately 2×10^3 spores under the skin of the shoulders. Sham SC challenged mice were handled in an identical manner but, 100 μ l of sterile PBS was administered SC. Mice were observed twice daily for 7 days. As mice died, tissues were collected for determination of bacterial concentrations. At the end of the 7-day study period all surviving mice were humanely euthanized.

Tissue bacterial concentrations

Lungs, liver, and spleen were collected immediately following death of each mouse. The tissues were weighed and manually homogenized. Following homogenization, an equal weight by volume of sterile PBS was added to each tissue homogenate and 1 ml of the homogenate was serially diluted 1:10 in sterile PBS. Twenty μ l of each dilution was plated onto BHI agar plates in triplicates and incubated at 37 °C for 24 h. Colony forming units were determined using the Miles and Misra method and calculations made to determine the CFUs/gram of tissue (Hedges, 2002).

Statistical analysis

Geometric mean titers were calculated by logarithmic transformation and group means compared by repeated measures ANOVA. Probit analysis was used to calculate LD₅₀ values. Survival rates were compared by Fischer exact tests. Kaplan–Meier survival analysis was used to construct survival curves. Mean time of death was compared using a one-way ANOVA with Tukey, LSD, and Bonferroni post-hoc analysis. Kruskal-Wallis tests were used to compare the colony forming units/gram of tissue. All analyses were conducted using IBM SPSS Statistics version 21.

RESULTS

Induction of anti-PA and neutralizing antibodies

Anti-PA IgG antibody titer responses were induced in each immunized horse. Geometric mean titers of 1:32,000 were achieved within two immunizations in 3 of 4 horses. Maximum anti-PA IgG titer induction was 1:128,000, though was not consistently maintained throughout the study period, Table 1. A consistent lethal toxin neutralizing antibody titer of 1:128 was induced following two immunizations in all horses and maintained throughout the study period. The maximum neutralizing titer observed was 1:256 for a single horse at one time point, Table 2.

Survival of A/J mice following Sterne strain challenge

Figure 1 and Table 3 show the results of the Kaplan–Meier survival curve, cumulative survival, and mean to death of A/J mice following an IN challenge with 1.5×10^4 spores and treated with immune plasma, purified immunoglobulins or placebo. Treatment with immune plasma at each time point resulted in a significantly prolonged mean time to death ($p < 0.001$), but did not significantly increase the number of mice (0/20 for 0 hr and 24 hr treatments) surviving to the end of the 7-day study period compared to controls ($p = 1.000$). When mice were administered 0.8 ml of purified immunoglobulins




Figure 1 Kaplan Meier survival curve following IN challenge and treatment with immune plasma or purified immunoglobulins. (A) Mice were IN challenged with 1.5×10^4 *B. anthracis* Sterne strain and treated with 0.8 ml of immune plasma at the time of inoculation (Tx 0 h, $n = 20$) or 24 h post-inoculation (Tx 24 h, $n = 20$). CON (naïve, $n = 20$) mice received the virulent challenge but were received 0.8 ml of naïve plasma at the time of inoculation. Non-infected mice served as treatment control mice and were sham inoculated with sterile PBS and treated with 0.8 ml of immune plasma at 0 h ($n = 20$). (B) Mice were IN challenged with 1.5×10^4 *B. anthracis* Sterne strain and treated with 0.8 ml of purified immunoglobulins at the time of inoculation (IgG 0 h, $n = 15$) or 24-hours post-inoculation (IgG 24 h, $n = 15$). CON (naïve, $n = 15$) mice received the virulent challenge but were received 0.8 ml of CON immunoglobulins at the time of inoculation. Non-infected mice served as treatment control mice and were challenged with IN sterile PBS and treated with 0.8 ml of purified immunoglobulins at the time of inoculation ($n = 15$).

Full-size  DOI: [10.7717/peerj.3907/fig-1](https://doi.org/10.7717/peerj.3907/fig-1)

Table 3 Cumulative survival and mean time to death following IN challenge. Mice were IN challenged with 1.5×10^4 *B. anthracis* Sterne strain and treated with 0.8 ml of immune plasma, purified immunoglobulins, or CON plasma/immunoglobulins at 0 h or 24 h post-infection. Two independent trials were conducted, first using immune plasma as treatment, second using purified immunoglobulins. Group numbers: Plasma Tx 0 h $n = 20$, Plasma Tx 24 h $n = 20$, IgG 0 h $n = 15$, IgG 24 h $n = 15$, CON $n = 20$ first experiment, $n = 15$ s experiment, Non-infected treatment control $n = 20$ first experiment, $n = 15$ s experiment.

	Cumulative survival (survivors/total)			Mean time to death (Days)		
	0 h	24 h		0 h	24 h	
Immune Plasma (Tx groups)	0/20	0/20	$p = 1.000$	4.1	3.9	$p < 0.001^a$
Purified Immunoglobulins (IgG groups)	14/15	12/15	$p < 0.001^a$	6.5	6.8	$p < 0.001^a$
CON (naïve) ^b	1/35	–		3.4	–	
Non-infected ^b	35/35	–		7.0	–	

Notes.

^a $p < 0.001$ for both treatments compared to CON (placebo) group.

^bData presented represents the combined total of mice used in each independent trial ($n = 20$ for immune plasma trial, $n = 15$ for purified immunoglobulin trial).

IP following IN challenge, 86% (13/15) survived to the end of trial when treated at the time of challenge and 80% (12/15) survived to the end of the trial when treated at 24 h post-challenge ($p < 0.001$, both treatment groups). In addition, treatment with purified immunoglobulins resulted in significantly prolonged survival time ($p < 0.001$, both treatment groups) when compared to mice treated with naïve plasma.

Figure 2 and Table 4 reveal similar results for the SC challenge in that immune plasma treatments did not result in significantly more mice surviving to the end of the study period ($p = 1.000$, 0/20 for 0 hr and 24 hr treatment). Immune plasma treatment in SC challenged mice did lead to significantly longer mean time to death ($p = 0.003$) however, in this case for the time 0 h treatment group only. When SC challenged mice were treated with purified immunoglobulins, 100% (15/15) treated at time 0 h survived to the end of the study while 86% (13/15) treated 24 h following challenge survived. These survival rates were significantly higher ($p < 0.001$, both treatment groups) than challenge control mice. Moreover, treatment at both time periods resulted in significantly longer ($p < 0.001$) mean time to death compared to control mice. All treatments of naïve plasma, immune plasma and purified immunoglobulins were well tolerated by the non-challenged treatment control mice and no morbidity/mortality was recorded in these groups for any of the conducted trials.

Bacterial concentrations

B. anthracis was successfully cultured from the lung, liver and spleen of infected mice in both challenge models. The tissues of non-infected control mice yielded no bacterial growth in any of the conducted trials. Although *B. anthracis* could be successfully isolated from the liver and spleen of mice following IN challenge, only lung tissue homogenates resulted in sufficiently high enough CFUs to accurately estimate bacterial loads. Treatment of IN challenged mice with immune plasma at either time point had no significant effect on the reduction in mean CFU/gram of lung tissue compared to non-treated challenge controls,




Figure 2 Kaplan Meier survival curve following SC challenge and treatment with immune plasma or purified immunoglobulin. (A) Mice were SC challenged with 2×10^3 *B. anthracis* Sterne strain and treated with 0.8 ml of immune plasma or CON (placebo, $n = 20$) at 0 h ($n = 20$) or 24 h post-infection ($n = 20$). Non-Infected served as treatment control mice and were challenged with SC sterile PBS and treated with 0.8 ml of immune plasma at 0 h ($n = 20$). (B) Mice were SC challenged with 2.3×10^3 *B. anthracis* Sterne strain and treated with 0.8 ml of purified immunoglobulins or CON immunoglobulins (placebo, $n = 15$) at 0 h ($n = 15$) or 24 h ($n = 15$) post-infection. Non-infected mice served as treatment control mice and were challenged with SC sterile PBS and treated with 0.8 ml of immune plasma at 0 h ($n = 15$).

Full-size  DOI: [10.7717/peerj.3907/fig-2](https://doi.org/10.7717/peerj.3907/fig-2)

Table 4 Cumulative survival and mean time to death following SC challenge. Mice were SC challenged with 2×10^3 *B. anthracis* Sterne strain and treated with 0.8 ml of immune plasma, purified immunoglobulins, or naïve equine plasma at 0 h or 24 h post-infection. Group numbers: Plasma Tx 0 h $n = 20$, Plasma Tx 24 h $n = 20$, IgG 0 h $n = 15$, IgG 24 h $n = 15$, CON $n = 20$ first experiment, $n = 15$ s experiment, Non-infected treatment $n = 20$ first experiment, $n = 15$ s experiment.

	Cumulative Survival (survivors/total)			Mean Time to Death (Days)		
	0 h	24 h		0 h	24 h	
Immune Plasma	0/20	0/20	$p = 1.000$	2.2	1.8	$p = 0.003^b$ $p = 0.380^c$
Purified Immunoglobulins	14/15	13/15	$p < 0.001^a$	7.0	6.8	$p < 0.001^a$
CON (naïve) ^d	0/35	–		1.7	–	
Non-infected ^d	35/35	–		7.0	–	

Notes.

^a $p < 0.001$ for both 0 hr and 24 hr treatment groups.

^b p value for 0 hr immune plasma treatment.

^c p value for 24 hr immune plasma treatment.

^dData presented represents the combined total of mice used in each independent trial ($n = 20$ for immune plasma trial, $n = 15$ for purified immunoglobulin trial).

Table 5 Mean colony forming units (CFUs)/ gram of tissue. The lungs, liver and spleen were collected at necropsy from each mouse upon death. Each organ was weighed and homogenized then serially diluted two-fold into sterile saline. Each dilution was plated onto BHI agar and the quantification of *B. anthracis* vegetative cells or spores was determined by the Miles and Mirsa method. Values represent the mean CFU/gram for each treatment group and challenge, NG = no quantifiable growth, p values denote significance compared to challenge control in Kruskal-Wallis comparison of means.

Mean CFU/gram of tissue

	IN challenge			SC challenge			
	Lung		Liver	Lung		Liver	
Immune Plasma 0 h Treatment ($n = 20$)	3.80×10^7	$p = 0.412$	NG	1.25×10^5	$p = 0.844$	7.4×10^4	$p = 0.233$
Immune Plasma 24 h Treatment ($n = 20$)	4.90×10^7	$p = 0.634$	NG	1.38×10^5	$p = 0.472$	7.75×10^4	$p = 0.380$
Purified Immunoglobulins 0 h Treatment ($n = 15$)	1.82×10^3	$p < 0.0001$	NG	NG	$p < 0.0001$	NG	$p < 0.0001$
Purified Immunoglobulins 24 h Treatment ($n = 15$)	9.94×10^4	$p < 0.0001$	NG	NG	$p < 0.0001$	1.11×10^3	$p < 0.0001$
CON (placebo, $n = 35$)	7.57×10^7		NG	1.15×10^5		3.62×10^5	
Non-infected ($n = 35$)	NG		NG	NG		NG	

Table 5. However, treatment of IN challenged mice with purified immunoglobulins at times 0 h and 24 h resulted in a 3-fold and 4-fold reduction in mean CFU/gram of lung tissue, respectively.

Following SC challenge, culture of lung and liver homogenates, but not spleen homogenates, yielded sufficient CFUs for accurate bacterial load estimation. Treatment of SC challenged mice with immune plasma at both time points had no significant effect on the reduction in mean CFU/gram of lung or liver tissue when compared to non-treated challenge controls, **Table 5**. When mice were treated with purified immunoglobulins, lung and liver tissue of all surviving mice resulted in no bacterial growth ($p < 0.0001$ for each).

DISCUSSION

The results of this study demonstrate the protective capacity of purified immunoglobulins against *B. anthracis* harvested from horses immunized with the Sterne strain spore vaccine. We have quantified the activity of equine hyper-immune plasma against important *B. anthracis* antigens such PA and lethal toxin that have in several studies been implicated as the primary targets for immune protection (Ivins et al., 1992; Pohl et al., 2013; Turnbull et al., 1986; Wright et al., 2010). Moreover, in a lethal challenge mice were protected following passive transfer of purified IgG immunoglobulins at 0 h and 24-hour post-exposure. These findings satisfy the proof-of-concept objectives set forth and indicate that further development of an equine-derived immunotherapeutic against *B. anthracis* may be warranted.

The *B. anthracis* Sterne strain vaccine has been shown to induce a broad humoral response against all three toxin components as well as inducing innate responses and modulating macrophage activity (Chakrabarty et al., 2006; Ivins et al., 1986; Langel et al., 2014; Little & Knudson, 1986). This diverse immune response has been shown to be fully protective in both toxin challenges and fully virulent anthrax infections (Ivins et al., 1986; Jackson, Wright & Armstrong, 1957; Little & Knudson, 1986; Romanov, 1980; Welkos & Friedlander, 1988). In this study, the plasma harvested from Sterne strain vaccinated horses demonstrated a strong and rapid anti-PA and anti-lethal toxin antibody titer. Elsewhere these targets and quantitative methods have been shown to correlate with survival following experimental challenge (Taft & Weiss, 2008).

The use of A/J mice has proven a valuable challenge model for active and passive immunization studies with *B. anthracis* (Duong, Chiaraviglio & Kirby, 2006; Welkos, Keener & Gibbs, 1986). The A/J strain of mice is homozygous for *Naip5^{Lgn1-s}* which imparts reduced macrophage bactericidal activity and increased susceptibility to bacterial infection (Goossens, 2009). Welkos, Keener & Gibbs (1986) defined this strain's susceptibility to *B. anthracis* Sterne strain by multiple routes of infection. This model provides a convenient example of a lethal challenge in that it greatly reduces the risk in handling an attenuated strain compared to fully virulent *B. anthracis* strains. This permits conducting such experiments in BSL 2 laboratory conditions. The limitation of the model is the potential for restricted relevance to fully virulent infections in larger animals and therefore extrapolation is precarious.

The treatments in this study were provided at the same time as the challenge or 24 h following challenge. It is unlikely that individuals exposed to *B. anthracis* would receive therapy at or near the time of infection, however treatment at 0 and 24 h post-infection provides a baseline to assess the protection of equine-derived hyperimmune plasma. Future therapeutic intervention studies that reflect the timing of infection and post-exposure prophylaxis are required. At this time, raxibacumab and AVIG are only approved as ancillary treatments alongside antimicrobial therapy and similar studies that evaluate the comparable effects of treatment with an equine-derived immunotherapeutic when combined with an antimicrobial are needed. The finding that treatment with purified

IgG immunoglobulins reduced the bacterial infection load of the lungs or liver, but did not completely clear all of the spores or vegetative *B. anthracis*, indicates that a single treatment at either time point may not have been entirely protective if the study period had been extended beyond 7 days. This also suggest that perhaps additional immunoglobulin treatments or combination therapies such as concurrent antimicrobials would be beneficial.

The lack of survival in both routes of infection (IN and SC) in mice treated with immune plasma suggests that the titer of transferred antibodies was too low to sufficiently neutralize all circulating toxin and provide protection. One hypothesis for the poor protection of these mice is that the passive titers were rapidly consumed by a high toxin burden, which permitted continued progression of the disease. This hypothesis is supported by the evidence that treatment with immune plasma did prolong the mean time to death. Moreover, the survival of mice treated with purified immunoglobulins likely infers a higher treatment success resulting from the transfer of a much higher titer of protective antibodies. Another potential mechanism for the poor protection of the immune plasma is the increased non-specific clearance of the foreign proteins by the immune system. In this study, the titers of specific antibodies present in mouse serum post-transfusion, though valuable, were not determined nor were the kinetics of transferred antibody titers following immunoglobulin administration.

Testing both these hypotheses begins with determining the kinetics of passive titers in mouse serum over time in the anti-PA ELISA and toxin neutralization assays. It's difficult to anticipate if the increased clearance of foreign protein would induce a measurable clinical effect, but all treatments were very well tolerated in non-challenged treatment control groups. Ideally, a correlation between the *in vivo* passive protection and TNA and ELISA titers would be made to define the dose of antibodies necessary to provide protection. The prolongation in mean to death suggests that multiple treatments of immune plasma may be necessary to establish full protection. Once the half-life of passive antibodies is determined then studies can be conducted to establish a dosing frequency necessary for successive treatments of immune plasma and/or a dose titration of purified immunoglobulins.

Mice that received immune plasma had similar bacterial concentrations (CFU/gram) upon death relative to CON treated mice, suggesting failure of the plasma to reduce bacterial concentrations. Treatment with purified immunoglobulins reduced the bacterial load in the lungs of IN challenged mice by fourfold, but did not eliminate the organisms. [Oscherwitz et al. \(2015\)](#) demonstrated that immunization of animals with spore antigens induced a protective antibody response that effectively limited germination. The passive treatments may have effectively conferred anti-spore antibodies and limited germination in treated mice. However, a longer period of observation may have allowed later germination of organisms and a delayed onset of disease.

In summary, though not exhaustive in its approach, this study establishes that an immune product with quantifiable anti-PA and lethal toxin neutralizing titers can be produced following vaccination of horses with the Sterne strain spore vaccine and can passively protect an alternate species from a lethal *B. anthracis* challenge. Future directions in developing equine-derived immunotherapeutics for anthrax include evaluation of the

kinetics of passively transferred antibodies in the A/J mouse Sterne challenge model as well as evaluation of the protection in other more relevant animal challenge models and against more virulent strains. The plasma and immunoglobulin treatments administered in this study were unprocessed full-length immunoglobulins contained in raw or minimally purified plasma preparations. The Fc portion of the heavy and light chains are the most reactive segments of foreign immunoglobulins and typically these subunits are cleaved and removed following pepsin digestion and immunopurification in final therapeutic preparations. In the development of an approved equine-derived based immunotherapeutic, extensive post collection processing must be undertaken and evaluated after each step. This study outlines the first of these steps and demonstrates that equine-derived purified immunoglobulins might be a viable strategy for anthrax counter measures.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Marc Caldwell conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Terri Hathcock and Kenny V. Brock conceived and designed the experiments, contributed reagents/materials/analysis tools.

Animal Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

All procedures described within this study involving the use of animals were approved by Auburn University Institutional Animal Care and Use Committee (protocol #2012-2105).

Data Availability

The following information was supplied regarding data availability:

The raw data has been supplied as a [Supplemental Dataset](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.3907#supplemental-information>.

REFERENCES

- Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, Westra H, Galloway D, Mateczun A, Goldman S, Groen H, Baillie LW. 2007. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against *Bacillus anthracis* infection and enhance endogenous immunity to anthrax. *Infection and Immunity* 75:5425–5433 DOI 10.1128/iai.00261-07.
- Arnon SS. 2007. Creation and development of the public service orphan drug Human Botulism Immune Globulin. *Pediatrics* 119:785–789 DOI 10.1542/peds.2006-0646.
- Bryskier A. 2002. *Bacillus anthracis* and antibacterial agents. *Clinical Microbiology and Infection* 8:467–478 DOI 10.1046/j.1469-0691.2002.00527.x.
- Canright CM. 1928. Human anthrax and its treatment. A report of three cases. *Chinese Medical Journal* 42:479–496 [in Chinese].
- Centers for Disease Control and Prevention (CDC). 2010. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies. Available at <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5902a1.htm> (accessed on 3 August 2017).
- Centers for Disease Control and Prevention (CDC). 2011. Tetanus. Available at <https://www.cdc.gov/tetanus/about/index.html> (accessed on 3 August 2017).
- Chakrabarty K, Wu W, Booth JL, Duggan ES, Coggeshall KM, Metcalf JP. 2006. *Bacillus anthracis* spores stimulate cytokine and chemokine innate immune responses in human alveolar macrophages through multiple mitogen-activated protein kinase pathways. *Infection and Immunity* 74:4430–4438 DOI 10.1128/iai.00446-06.
- Corey A, Migone TS, Bolmer S, Fiscella M, Ward C, Chen C, Meister G. 2013. *Bacillus anthracis* protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits. *Toxins (Basel)* 5:120–138 DOI 10.3390/toxins5010120.
- Cui X, Li Y, Moayeri M, Choi GH, Subramanian GM, Li X, Haley M, Fitz Y, Feng J, Banks SM, Leppla SH, Eichacker PQ. 2005. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. *Journal of Infectious Diseases* 191:422–434 DOI 10.1086/427189.
- Duong S, Chiaraviglio L, Kirby JE. 2006. Histopathology in a murine model of anthrax. *International Journal of Experimental Pathology* 87:131–137 DOI 10.1111/j.0959-9673.2006.00473.x.
- Goossens PL. 2009. Animal models of human anthrax: the Quest for the Holy Grail. *Molecular Aspects of Medicine* 30:467–480 DOI 10.1016/j.mam.2009.07.005.
- Hedges AJ. 2002. Estimating the precision of serial dilutions and viable bacterial counts. *International Journal of Food Microbiology* 76:207–214 DOI 10.1016/S0168-1605(02)00022-3.
- Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty J-EC, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA, the Workgroup on Anthrax Clinical Guidelines. 2014. Centers for disease control

- and prevention expert panel meetings on prevention and treatment of anthrax in adults. *Emerging Infectious Diseases* **20**:e130687 DOI [10.3201/eid2002.130687](https://doi.org/10.3201/eid2002.130687).
- Hering D, Thompson W, Hewetson J, Little S, Norris S, Pace-Templeton J. 2004.** Validation of the anthrax lethal toxin neutralization assay. *Biologicals* **32**:17–27 DOI [10.1016/j.biologicals.2003.09.003](https://doi.org/10.1016/j.biologicals.2003.09.003).
- Hewetson JF, Little SF, Ivins BE, Johnson WM, Pittman PR, Brown JE, Norris SL, Nielsen CJ. 2008.** An *in vivo* passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. *Vaccine* **26**:4262–4266 DOI [10.1016/j.vaccine.2008.05.068](https://doi.org/10.1016/j.vaccine.2008.05.068).
- Hodgson H. 1941.** Cutaneous Anthrax. *Lancet* **237**:811–813 DOI [10.1016/S0140-6736\(00\)61181-9](https://doi.org/10.1016/S0140-6736(00)61181-9).
- Huang E, Pillai SK, Bower WA, Hendricks KA, Guarnizo JT, Hoyle JD, Gorman SE, Boyer AE, Quinn CP, Meaney-Delman D. 2015.** Antitoxin treatment of inhalation anthrax: a systematic review. *Health Security* **13**:365–377 DOI [10.1089/hs.2015.0032](https://doi.org/10.1089/hs.2015.0032).
- Ivins BE, Ezzell Jr JW, Jemski J, Hedlund KW, Ristroph JD, Leppla SH. 1986.** Immunization studies with attenuated strains of *Bacillus anthracis*. *Infection and Immunity* **52**:454–458.
- Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. 1992.** Immunization against anthrax with *Bacillus anthracis* protective antigen combined with adjuvants. *Infection and Immunity* **60**:662–668.
- Jackson FC, Wright GG, Armstrong J. 1957.** Immunization of cattle against experimental anthrax with alum-precipitated protective antigen or spore vaccine. *American Journal of Veterinary Research* **18**:771–777.
- Kammanadiminti S, Patnaikuni RK, Comer J, Meister G, Sinclair C, Kodihalli S. 2014.** Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax. *PLOS ONE* **9**:e106393 DOI [10.1371/journal.pone.0106393](https://doi.org/10.1371/journal.pone.0106393).
- Karginov VA, Robinson TM, Riemenschneider J, Golding B, Kennedy M, Shiloach J, Alibek K. 2004.** Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of *Bacillus anthracis*. *FEMS Immunology and Medical Microbiology* **40**:71–74 DOI [10.1016/S0928-8244\(03\)00302-X](https://doi.org/10.1016/S0928-8244(03)00302-X).
- Kummerfeldt CE. 2014.** Raxibacumab: potential role in the treatment of inhalational anthrax. *Infection and Drug Resistance* **7**:101–109 DOI [10.2147/idr.s47305](https://doi.org/10.2147/idr.s47305).
- Langel FD, Chiang CY, Lane D, Kenny T, Ojeda JF, Zhong Y, Che J, Zhou Y, Ribot W, Kota KP, Bavari S, Panchal RG. 2014.** Alveolar macrophages infected with Ames or Sterne strain of *Bacillus anthracis* elicit differential molecular expression patterns. *PLOS ONE* **9**:e87201 DOI [10.1371/journal.pone.0087201](https://doi.org/10.1371/journal.pone.0087201).
- Leysath CE, Chen KH, Moayeri M, Crown D, Fattah R, Chen Z, Das SR, Purcell RH, Leppla SH. 2011.** Mouse monoclonal antibodies to anthrax edema factor protect against infection. *Infection and Immunity* **79**:4609–4616 DOI [10.1128/iai.05314-11](https://doi.org/10.1128/iai.05314-11).
- Little SF, Knudson GB. 1986.** Comparative efficacy of *Bacillus anthracis* live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. *Infection and Immunity* **52**:509–512.

- Mazumdar S.** 2009. Raxibacumab. *MAbs* 1:531–538 DOI [10.4161/mabs.1.6.10195](https://doi.org/10.4161/mabs.1.6.10195).
- Migone TS, Bolmer S, Zhong J, Corey A, Vasconcelos D, Buccellato M, Meister G.** 2015. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. *Antimicrobial Agents and Chemotherapy* 59:1145–1151 DOI [10.1128/aac.04606-14](https://doi.org/10.1128/aac.04606-14).
- Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD.** 2009. Raxibacumab for the treatment of inhalational anthrax. *New England Journal of Medicine* 361:135–144 DOI [10.1056/NEJMoa0810603](https://doi.org/10.1056/NEJMoa0810603).
- Mitchell W.** 1905. Case of cutaneous anthrax treated without excision with sclavo's anti-anthrax serum: recovery. *British Medical Journal* 2:118–120.
- Moayeri M, Leppla SH, Vrentas C, Pomerantsev AP, Liu S.** 2015. Anthrax pathogenesis. *Annual Review of Microbiology* 69:185–208 DOI [10.1146/annurev-micro-091014-104523](https://doi.org/10.1146/annurev-micro-091014-104523).
- Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH.** 2013. Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. *Antimicrobial Agents and Chemotherapy* 57:5684–5692 DOI [10.1128/aac.00458-13](https://doi.org/10.1128/aac.00458-13).
- Oscherwitz J, Feldman D, Yu F, Cease KB.** 2015. Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax. *Vaccine* 33:430–436 DOI [10.1016/j.vaccine.2014.11.042](https://doi.org/10.1016/j.vaccine.2014.11.042).
- Pezard C, Berche P, Mock M.** 1991. Contribution of individual toxin components to virulence of *Bacillus anthracis*. *Infection and Immunity* 59:3472–3477.
- Pillai SK, Huang E, Guarnizo JT, Hoyle JD, Katharios-Lanwermyer S, Turski TK, Bower WA, Hendricks KA, Meaney-Delman D.** 2015. Antimicrobial treatment for systemic anthrax: analysis of cases from 1945 to 2014 identified through a systematic literature review. *Health Security* 13:355–364 DOI [10.1089/hs.2015.0033](https://doi.org/10.1089/hs.2015.0033).
- Pohl MA, Rivera J, Nakouzi A, Chow SK, Casadevall A.** 2013. Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. *Infection and Immunity* 81:1880–1888 DOI [10.1128/iai.01328-12](https://doi.org/10.1128/iai.01328-12).
- Ragazzi CA.** 1954. Achille Sclavo, teacher and precursor of current preventive medicine. *Annali della Sanita Pubblica* 15:453–461.
- Remy KE, Cui X, Li Y, Sun J, Solomon SB, Fitz Y, Barochia AV, Al-Hamad M, Moayeri M, Leppla SH, Eichacker PQ.** 2015. Raxibacumab augments hemodynamic support and improves outcomes during shock with *B. anthracis* edema toxin alone or together with lethal toxin in canines. *Intensive Care Medicine Experimental* 3:9–23 DOI [10.1186/s40635-015-0043-4](https://doi.org/10.1186/s40635-015-0043-4).
- Romanov GI.** 1980. Preparation, control and application of anthrax vaccine in USSR. *Archiv Fur Experimentelle Veterinarmedizin* 34:119–122 [in German].
- Santee HE.** 1923. Anthrax and its treatment. *Annals of Surgery* 78:326–331 DOI [10.1097/0000658-192309000-00003](https://doi.org/10.1097/0000658-192309000-00003).
- Sclavo A.** 1954. Serum treatment of anthrax in man. *Revista d'Igiene e Sanità* 14:161–175 [in Italian].

- Staats HF, Alam SM, Scarce RM, Kirwan SM, Zhang JX, Gwinn WM, Haynes BF. 2007.** In vitro and *in vivo* characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. *Infection and Immunity* 75:5443–5452 DOI 10.1128/iai.00529-07.
- Taft SC, Weiss AA. 2008.** Neutralizing activity of vaccine-induced antibodies to two *Bacillus anthracis* toxin components, lethal factor and edema factor. *Clinical and Vaccine Immunology* 15:71–75 DOI 10.1128/cvi.00321-07.
- Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. 1986.** Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. *Infection and Immunity* 52:356–363.
- Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. 1988.** Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. *Medical Microbiology and Immunology* 177:293–303.
- United States Food and Drug Administration (US-FDA). 2013.** Raxibacumab for anthrax. *Medical Letter on Drugs and Therapeutics* 55:27–28.
- United States Food and Drug Administration (US-FDA). 2015.** FDA approves treatment for inhalation anthrax. Available at <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm> (accessed on 3 August 2017).
- Von Behring E. 2008.** Serum therapy in therapeutics and medical science. Nobel Lecture. December 12, 1901. Available at https://www.nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-lecture.html.
- Von Stabsarzt B. 1991.** Über das zustandekommen der diphtherie-immunität und der tetanus-immunität bei thieren. *Molecular Immunology* 28:1319–1320 DOI 10.1016/0161-5890(91)90033-G.
- Weiss S, Kobiler D, Levy H, Pass A, Ophir Y, Rothschild N, Tal A, Schlomovitz J, Altboum Z. 2011.** Antibiotics cure anthrax in animal models. *Antimicrobial Agents and Chemotherapy* 55:1533–1542 DOI 10.1128/aac.01689-10.
- Welkos SL, Friedlander AM. 1988.** Comparative safety and efficacy against *Bacillus anthracis* of protective antigen and live vaccines in mice. *Microbial Pathogenesis* 5:127–139 DOI 10.1016/0882-4010(88)90015-0.
- Welkos SL, Keener TJ, Gibbs PH. 1986.** Differences in susceptibility of inbred mice to *Bacillus anthracis*. *Infection and Immunity* 51:795–800.
- Wright JG, Quinn CP, Shadomy S, Messonnier N. 2010.** Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. *MMWR Recommendations and Reports* 59:1–30.